Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 729-732

  Montaner, Julio S G ^a   Mo, Theresa ^a   Raboud, Janet M ^a   Rae, Sandra ^a   Alexander, Christopher S ^a   Zala, Carlos ^c   Rouleau, Danielle ^b   Harrigan, P Richard ^a,d  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c FUNDACIÓN HUÉSPED   (Argentina)

^d ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA; LAMIVUDINE; STAVUDINE; VIRUS DNA;

ARTICLE; CLINICAL ARTICLE; DNA DETERMINATION; DNA SEQUENCE; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYUREA; LAMIVUDINE; LOGISTIC MODELS; MUTATION; NUCLEIC ACID SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; VIRAL LOAD; ZIDOVUDINE;

EID: 0034009849     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315243     Document Type: Article

References (15)

1. Montaner JS, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175:801-6.
2. Rouleau D, Conway B, Raboud J, et al. Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study. J Infect Dis 1997;176:1156-60.
3. Harrigan PR, Kinghorn I, Bloor S, et al. Significance of amino acid variation at human immunodeficiency virus type-1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996;70:5930-4.
4. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996;276:146-54.
5. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:129.
6. Lori F, Malykh AG, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997;13:1403-9.
7. De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pool gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997;176:899-903.
8. Palmer S, Shafer R, Merigan T. Both nucleoside and nucleotide analogues are potentiated by hydroxyurea against drug-susceptible and drug-resistant HIV isolates [abstract 3]. In: Program and abstracts: 2nd International Workshop on HIV Drug Resistance and Treatment Strategies (Lake Maggiore, Italy). Atlanta: International Medical Press, 1998.
9. Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis 1995;171:1172-9.
10. Lori F, Jessen H, Lieberman J, Clerici M, Tinelli C, Lisziewicz J. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum Retroviruses 1999;15:619-24.
11. Katlama C, Valantin MA, Matheron S, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. Ann Intern Med 1998;129:525-31.
12. Lin PF, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994;170:1157-64.
13. Soriano V, Dietrich U, Villalba N, et al. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997;11:696-7.
14. Lukashov VV, de Jong JJ, Huismans R, et al. Evolutionary and phenotypic analysis of multidrug-resistant HIV-1 strains with combinations of insertions between codons 68 and 69 and amino acid changes in reverse transcriptase [abstract 122]. In: 6th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago). Alexandria, VA: Infectious Diseases Society of America, 1999.
15. Bloor S, Hertogs K, Desmet RL, Pauwels R, Larder BA. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples [abstract 15]. In: Program and abstracts: 2nd International Workshop on HIV Drug Resistance and Treatment Strategies (Lake Maggiore, Italy). Atlanta: International Medical Press, 1998.